nerves, smoothing the skin, increasing blood circulation, redistributing or eliminating fatty tissue, and developing the chest and lungs.

Disposition: 5-2-61. Default—destruction.

DRUG FOR VETERINARY USE*

6780. Piperazine hog and poultry wormer. (F.D.C. No. 45790. S. No. 22-037 R.)

QUANTITY: 31 1-qt. btls. at Middlebury, Ind.

Shipped: 9-7-60, from Toledo, Ohio, by Miller Chemical Co.

LABEL IN PART: "Piperazine Hog & Poultry Wormer Active Ingredient: Each 100 cc Contains 17.08 grams of Piperazine Base Hexahydrate. * * * Directions for use-Miller's Piperazine-A Liquid Wormer For Swine & Poultry."

LIBELED: 5-5-61, N. Dist. Ind.

CHARGE: 502(a)—when shipped, the label contained false and misleading representations that the article was adequate and effective when used as directed in treatment for removing or controlling nodular and round worms from swine and round worms (Ascaridia galli) from poultry.

DISPOSITION: 6-16-61. Default—destruction.

INDEX TO NOTICES OF JUDGMENT D. D. N. J. NOS. 6741 TO 6780

PRODUCTS.

-		•
N.	J. No.	N.J. No.
Abunda Beauty device	6776	Devices 6748, 6749, 6758, 6775–6778
Air purifier device	6775	Duodenal ulcers, remedy for 6762
All-In-One capsules	6764	Electronic Magnetic Model G de-
Altocaps capsules	6745	vice 6748, 6749
Androgenic substance	6745	Equanil tablets (imitation) 6757
Armatinic liquid	6742	Erasurage device 6777
Arthritis, remedy for. See Rheu-		Family Plan Vitafood Supple-
matism, remedy for.		ment tablets 6774
Asthma, remedy for (device)	6775	Ferbetex tablets 6741
Barium sulfate	6752	Ferrous sulfate tablets 6751
Bhaji tablets	6761	Figuremaker device 6778
Biphetamine-T 20	6743	Hay fever, remedy for (device) _ 6775
12½	6743	Insta-Pep tablets ¹ 6746
Bursitis, remedy for. See Rheu-		Iro-Jex injectable 6744
matism, remedy for.		Isoproterenol hydrochloride sub-
Bust developer (device)	6776	lingual tablets 6754
Cernelle Pollitabs	6771	Kongo-Kit massage device 6779
Chick starter (medicated)	6760	
Chirata, powdered	6761	
Coach-Aid Special Formula pills_	6773	Lecitabs6763
Stim-O-Stam Food Supplement		Lecithin tablets 6763
tablets	6773	Lumbago, remedy for. See Rheu-
Cosmetics (subject to the drug		matism, remedy for.
provisions of the Act) 6777,	6778	Mavene wafers 6762
Cough syrup, Olbas	6768	Micronaire device 6775
Delamer minerals in sea water	6766	Neuralgia, remedy for. See
Deronil tablets	6747	Rheumatism, remedy for.

^{*}See also No. 6760.

¹ (6746) Prosecution contested. Contains memorandum and order of the court.

U.S. Department of Health, Education, and Welfare

FOOD AND DRUG ADMINISTRATION

NOTICES OF JUDGMENT UNDER THE FEDERAL FOOD, DRUG, AND COSMETIC ACT

[Given pursuant to section 705 of the Food, Drug, and Cosmetic Act]

6781-6820

DRUGS AND DEVICES

The cases reported herewith were instituted in the United States district courts by United States attorneys, acting upon reports submitted by the Department of Health, Education, and Welfare. They involve drugs and devices which were adulterated or misbranded within the meaning of the Act when introduced into and while in interstate commerce or while held for sale after shipment in interstate commerce. These cases involve seizure proceedings in which decrees of condemnation were entered after default or consent. The seizure proceedings are civil actions taken against the goods alleged to be in violation. Published by direction of the Secretary of Health, Education, and Welfare.

GEO. P. LARRICK, Commissioner of Food and Drugs.

WASHINGTON, D.C., November 29, 1962.

CONTENTS*

•	
d without effec- $ $ Drugs and devices a	actionable
n 190 because of deviation	tion from
of prescription official or own stand	ndards 19
ements 192 Drugs for human use	19
vice actionable Drug for veterinary use	se 20
ailure to bear Drugs and devices a	actionable
tions or warning because of false and m	misleading
197 claims	20
use 197 Drug actionable because	se of omis-
nary use 198 sion of, or unsatisfa gredient statements_	21
Index	21
n use 197 Drug actionable because sion of, or unsatisfa	se of omis- factory in-

^{*}For failure to bear a label containing an accurate statement of the quantity of the contents. See Nos. 6786, 6794, 6820; failure to bear a label containing the name and place of business of the manufacturer, packer, or distributor, Nos. 6783, 6784, 6786, 6801 6815, 6820; cosmetics, actionable under the drug provisions of the Act, Nos. 6815-6817.

SECTIONS OF FEDERAL FOOD, DRUG, AND COSMETIC ACT INVOLVED IN VIOLATIONS REPORTED IN D.D.N.J. NOS. 6781-6820

Adulteration, Section 501(c), the article was not subject to the provisions of Section 501(b), and its strength differed from, or its purity or quality fell below, that which it purported or was represented to possess.

Misbranding, Section 502(a), the labeling of the article was false and misleading; Section 502(b), the article was in package form, and it failed to bear a label containing (1) the name and place of business of the manufacturer, packer, or distributor, and (2) an accurate statement of the quantity of the contents in terms of weight, measure, or numerical count; Section 502(e), the article was a drug not designated solely by a name recognized in an official compendium, and its label failed to bear (1) the common or usual name of the drug, and (2), in the case where the article was fabricated from two or more ingredients, the common or usual name of each active ingredient; Section 502(f), the labeling of the article failed to bear (1) adequate directions for use, and (2) adequate warnings against use in those pathological conditions, or by children, where its use may be dangerous to health, or against unsafe dosage or methods or duration of administration or application, in such manner and form, as are necessary for the protection of users; Section 503(b)(4), the article was a drug subject to Section 503(b)(1), and its label failed to bear the statement "Caution: Federal law prohibits dispensing without prescription."

New-drug violation, Section 505(a), the article was a new drug within the meaning of Section 201(p), which was introduced into interstate commerce, and an application filed pursuant to Section 505(b) was not effective with respect to such drug.

NEW DRUGS SHIPPED WITHOUT EFFECTIVE APPLICATION

6781. Entoquel syrup and Entoquel with Neomycin syrup (2 seizure actions). (F.D.C. Nos. 46217, 46220. S. Nos. 88-031/2 R, 91-339/40 R.)

QUANTITY: 20 6-oz. btls. of Entoquel syrup and 21 6-oz. btls. of Entoquel with Neomycin syrup at Baltimore, Md.; 44 6-oz. btls. of Entoquel syrup and 59 6-oz. btls. of Entoquel with Neomycin syrup at Jamaica, Queens, N.Y.

SHIPPED: Between 2-6-61 and 2-10-61, from Kenilworth, N.J., by White Laboratories, Inc.

Label In Part: "Entoquel Syrup (Thihexinol Methyl Bromide) * * * Each Teaspoon (5 cc) contains * * * Thihexinol Methyl Bromide - 5 mg. Alcohol - 1%" and "Entoquel With Neomycin Syrup * * * Each Teaspoon (5 cc) contains * * * Thihexinol (Entoquel) - 5 mg. Neomycin (from the sulfate) - 50 mg. Alcohol - 0.5%."

Accompanying Labeling: A promotional form letter mailed on or about 4-10-61, addressed to "Dear Doctor"; a promotional folder mailed on or about 4-27-61, entitled "Are opiates now outmoded in pediatric diarrhea?"; and a promotional folder mailed in June or July 1961, entitled "Are opiates now outmoded in pediatric diarrhea?" with a picture of an infant and a bottle of paregoric on the cover.

LIBELED: 8-1-61, Dist., Md., and E. Dist, N.Y.

CHARGE: 502(a)—when shipped and while held for sale, the labeling of the articles was false and misleading: